By Sheeba M. | May 19, 2026
Cannabis M&A Heats Up: Curaleaf Leads $5B Consolidation Sprint
The cannabis M&A game just got serious. Curaleaf Holdings disclosed a $180M deal pipeline at an investor conference last week, signaling that the big players are locking in smaller operators before the rescheduling premium kicks in.
This is the consolidation wave everyone predicted—and nobody’s positioned for it yet.
Here’s the math: Small-cap MSOs are trading at 3-5x EBITDA. Big players like CURLF and GTBIF are trading at 6-8x. Federal rescheduling could compress those multiples to 8-12x in 12 months. That means acquirers have a shrinking window to buy cheap.
Look at the targets: Verano Holdings, Ascend Wellness, and smaller single-state operators. All are trading below intrinsic value. All have positive EBITDA. All could command 25-40% premiums post-rescheduling.
The acquirer thesis is getting clearer too. Trulieve‘s dominance in Florida could extend to adjacent markets via acquisition. Cresco Labs‘ vertical integration model becomes more valuable with scale. Even Verano’s high-margin flower could attract a strategic buyer.
By September, industry insiders estimate $4-5B in total announced M&A deals. That volume would represent the largest consolidation wave since 2021—and unlike 2021, these deals have real financing backing them.
Sources
- Curaleaf Investor Relations — M&A strategy and deal pipeline
- Moody’s Cannabis M&A Report — Consolidation trends
- SEC Filings — MSO disclosures and capital allocation
Track cannabis stocks with the Weedstock Real-Time Tracker